tradingkey.logo

PolyPid Ltd

PYPD
3.850USD
+0.060+1.58%
Horário de mercado ETCotações atrasadas em 15 min
60.27MValor de mercado
PerdaP/L TTM

Mais detalhes de PolyPid Ltd Empresa

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Informações de PolyPid Ltd

Código da empresaPYPD
Nome da EmpresaPolyPid Ltd
Data de listagemJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Número de funcionários57
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 26
Endereço18 Hasivim Street, P.O Box 7126
CidadePETAH TIKVA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal4917002
Telefone972747195700
Sitehttps://www.polypid.com
Código da empresaPYPD
Data de listagemJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad

Executivos da empresa PolyPid Ltd

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Aurum Ventures M.K.I.
19.69%
Centaurus Investments Limited
7.08%
Rosalind Advisors, Inc.
6.23%
AIGH Capital Management, LLC.
4.93%
Worth Venture Partners, LLC
4.67%
Outro
57.40%
Investidores
Investidores
Proporção
Aurum Ventures M.K.I.
19.69%
Centaurus Investments Limited
7.08%
Rosalind Advisors, Inc.
6.23%
AIGH Capital Management, LLC.
4.93%
Worth Venture Partners, LLC
4.67%
Outro
57.40%
Tipos de investidores
Investidores
Proporção
Venture Capital
19.69%
Hedge Fund
12.56%
Holding Company
7.08%
Individual Investor
5.87%
Private Equity
4.93%
Investment Advisor/Hedge Fund
4.67%
Corporation
3.76%
Investment Advisor
0.79%
Research Firm
0.53%
Outro
40.12%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
27
6.76M
43.18%
+2.23M
2025Q2
41
7.60M
74.58%
+1.39M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
2023Q2
57
472.86K
36.65%
+91.51K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Aurum Ventures M.K.I.
3.08M
19.69%
+1.06M
+52.19%
Jun 30, 2025
Centaurus Investments Limited
1.11M
7.08%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
975.46K
6.23%
-42.56K
-4.18%
Jun 30, 2025
AIGH Capital Management, LLC.
462.54K
2.95%
-48.41K
-9.47%
Jun 30, 2025
Worth Venture Partners, LLC
731.57K
4.67%
+302.14K
+70.36%
Jun 30, 2025
Nir (Yehuda)
613.91K
3.92%
+62.60K
+11.36%
Mar 31, 2025
Hewlett Fund, L.P.
587.92K
3.76%
+338.44K
+135.66%
Feb 26, 2025
Triple Gate Capital, LP
465.84K
2.98%
+465.84K
--
Feb 26, 2025
Lukach (Aharon)
299.55K
1.91%
-5.64K
-1.85%
Mar 31, 2025
Dafna Capital Management, LLC
207.90K
1.33%
-83.37K
-28.62%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Data
Tipo
Proporção
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
KeyAI